TABLE 3.

GMFR of S_1w IgG, RBD_w IgG and sVNT_w in the participants

	Pooled		SpikoGen®		Inactivated virus		Viral vector
	SpikoGen®	Placebo	SpikoGen®	Placebo	SpikoGen®	Placebo	SpikoGen®	Placebo
sVNTw
Day 14 (n)	199	39	41	9	109	21	49	9
GMFR	18.83	1.34	11.33	1.46	25.77	1.40	14.32	1.13
95% CI	(14.71–24.10)	(1.15–1.56)	(6.45–19.92)	(1.04–2.04)	(18.51–35.87)	(1.09–1.79)	(8.81–23.27)	(0.97–1.31)
S1w‐IgG
Day 14 (n)	199	39	41	9	109	21	49	9
GMFR	5.92	1.09	5.11	1.18	7.49	1.11	3.97	0.98
95% CI	(4.94–7.10)	(0.99–1.21)	(3.10–8.44)	(0.89–1.56)	(5.93–9.45)	(0.98–1.25)	(2.91–5.42)	(0.74–1.30)
RBDw‐IgG
Day 14 (n)	199	39	41	9	109	21	49	9
GMFR	11.24	1	7.59	1.11	17.06	1.05	6.81	0.81
95% CI	(8.77–14.42)	(0.87–1.15)	(4.29–13.41)	(0.87–1.43)	(12.25–23.77)	(0.93–1.18)	(3.89–9.83)	(0.47–1.40)

Note: The 95% confidence interval (CI) for geometric mean fold rise (GMFR) was calculated based on the t‐distribution of the log‐transformed values, then back‐transformed to the original scale for presentation.